1. The Continuum of Thyroid Disorders Related to Immune Checkpoint Inhibitors: Still Many Pending Queries
    Maria V. Deligiorgi et al, 2021, Cancers CrossRef
  2. Transient Thyroiditis Followed by Exacerbation of Hypothyroidism After Immune Checkpoint Inhibitor Therapy (Nivolumab and Ipilimumab) in a Patient With Pre-existing Autoimmune Hypothyroidism: A Case Report
    Guy Hayakawa et al, 2023, Cureus CrossRef
  3. Association of Immune Related Adverse Events With Efficacy of Immune Checkpoint Inhibitors and Overall Survival in Cancers: A Systemic Review and Meta-analysis
    Yong Fan et al, 2021, Frontiers in Oncology CrossRef
  4. Patients with melanoma treated with immune checkpoint inhibitors who had non-thyroid endocrine and skin immune-related adverse events have better prognosis: A systematic review and meta-analysis
    Qian Sun et al, 2022, Frontiers in Oncology CrossRef
  5. Safety and efficacy of PD-1/PD-L1 blockade in patients with preexisting antinuclear antibodies
    T. Sakakida et al, 2020, Clinical and Translational Oncology CrossRef

  6. Correlation of Immune-Related Adverse Events and Effects of Pembrolizumab Monotherapy in Patients with Non-Small Cell Lung Cancer


    Susumu Noguchi et al, 2020, Lung Cancer: Targets and Therapy CrossRef
  7. Thyroid Dysfunction in Lung Cancer Patients Treated with Immune Checkpoint Inhibitors (ICIs): Outcomes in a Multiethnic Urban Cohort
    Angelica D’Aiello et al, 2021, Cancers CrossRef
  8. Usage Patterns and Incidence of Thyroid-related Adverse Events in Patients Treated with PD-1 Inhibitors
    Seoyoung Hwang et al, 2021, Korean Journal of Clinical Pharmacy CrossRef
  9. Immune Checkpoint Inhibitor-induced Thyroid Disorders: A Single Center Experience
    Poupak Fallahi et al, 2023, Current Pharmaceutical Design CrossRef
  10. Prediction-based prompt levothyroxine replacement to prevent a hypothyroid state after immune-related adverse events involving the thyroid gland
    Ichiro Yamauchi et al, 2023, Endocrine Journal CrossRef
  11. Pembrolizumab-Induced Thyroiditis Shows PD-L1Expressing Histiocytes and Infiltrating T Cells in Thyroid Tissue - A Case Report
    Jörg Jabkowski et al, 2021, Frontiers in Immunology CrossRef
  12. Patterns and outcomes of immune-related adverse events in solid tumor patients treated with immune checkpoint inhibitors in Thailand: a multicenter analysis
    Nuttapong Ngamphaiboon et al, 2021, BMC Cancer CrossRef
  13. Case Report: Lymphocytosis Associated With Fatal Hepatitis in a Thymoma Patient Treated With Anti-PD1: New Insight Into the Immune-Related Storm
    Antonella Argentiero et al, 2020, Frontiers in Oncology CrossRef
  14. Quantitative Dynamic 18F-FDG PET/CT in Survival Prediction of Metastatic Melanoma under PD-1 Inhibitors
    Christos Sachpekidis et al, 2021, Cancers CrossRef
  15. Prediction of Immune-Checkpoint Blockade Monotherapy Response in Patients With Melanoma Based on Easily Accessible Clinical Indicators
    Hwa Kyung Byun et al, 2021, Frontiers in Oncology CrossRef
  16. Factors Determining Long-Term Antitumor Responses to Immune Checkpoint Blockade Therapy in Melanoma
    Kimberly Loo et al, 2022, Frontiers in Immunology CrossRef